Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
- PMID: 1710657
- PMCID: PMC6575424
- DOI: 10.1523/JNEUROSCI.11-06-01649.1991
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
Abstract
We previously found a relative sparing of somatostatin and neuropeptide Y neurons 1 week after producing striatal lesions with NMDA receptor agonists. These results are similar to postmortem findings in Huntington's disease (HD), though in this illness there are two- to threefold increases in striatal somatostatin and neuropeptide Y concentrations, which may be due to striatal atrophy. In the present study, we examined the effects of striatal excitotoxin lesions at 6 months and 1 yr, because these lesions exhibit striatal shrinkage and atrophy similar to that occurring in HD striatum. At 6 months and 1 yr, lesions with the NMDA receptor agonist quinolinic acid (QA) resulted in significant increases (up to twofold) in concentrations of somatostatin and neuropeptide Y immunoreactivity, while concentrations of GABA, substance P immunoreactivity, and ChAT activity were significantly reduced. In contrast, somatostatin and neuropeptide Y concentrations did not increase 6 months after kainic acid (KA) or alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) lesions. At both 6 months and 1 yr, QA lesions showed striking sparing of NADPH-diaphorase neurons as compared with both AMPA and KA lesions, neither of which showed preferential sparing of these neurons. Long-term QA lesions also resulted in significant increases in concentrations of both 5-HT and 5-hydroxyindoleacetic acid (HIAA), similar to findings in HD. Chronic QA lesions therefore closely resemble the neurochemical features of HD, because they result in increases in somatostatin and neuropeptide Y and in 5-HT and HIAA. These findings strengthen the possibility that an NMDA receptor-mediated excitotoxic process could play a role in the pathogenesis of HD.
Similar articles
-
Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.Synapse. 1989;3(1):38-47. doi: 10.1002/syn.890030106. Synapse. 1989. PMID: 2563916
-
Neurochemical characterization of excitotoxin lesions in the cerebral cortex.J Neurosci. 1991 Jan;11(1):147-58. doi: 10.1523/JNEUROSCI.11-01-00147.1991. J Neurosci. 1991. PMID: 1670782 Free PMC article.
-
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.Nature. 1986 May 8-14;321(6066):168-71. doi: 10.1038/321168a0. Nature. 1986. PMID: 2422561
-
Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease.Brain Res Brain Res Rev. 2000 Nov;34(1-2):80-101. doi: 10.1016/s0165-0173(00)00039-4. Brain Res Brain Res Rev. 2000. PMID: 11086188 Review.
-
Glutamate and Huntington's disease.Med J Aust. 1981 Oct 31;2(9):460-5. doi: 10.5694/j.1326-5377.1981.tb112939.x. Med J Aust. 1981. PMID: 6119604 Review.
Cited by
-
Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation.Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):704-15. doi: 10.1007/s00259-007-0651-7. Epub 2007 Dec 15. Eur J Nucl Med Mol Imaging. 2008. PMID: 18080815
-
Huntington's disease and Group I metabotropic glutamate receptors.Mol Neurobiol. 2011 Feb;43(1):1-11. doi: 10.1007/s12035-010-8153-1. Epub 2010 Dec 9. Mol Neurobiol. 2011. PMID: 21153060 Review.
-
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8727-32. doi: 10.1073/pnas.96.15.8727. Proc Natl Acad Sci U S A. 1999. PMID: 10411943 Free PMC article.
-
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Neuroscience. 2011 Dec 15;198:252-73. doi: 10.1016/j.neuroscience.2011.08.052. Epub 2011 Aug 27. Neuroscience. 2011. PMID: 21907762 Free PMC article. Review.
-
Oxidation of the aromatic amino acids tryptophan and tyrosine disrupts their anabolic effects on bone marrow mesenchymal stem cells.Mol Cell Endocrinol. 2015 Jul 15;410:87-96. doi: 10.1016/j.mce.2015.01.034. Epub 2015 Jan 28. Mol Cell Endocrinol. 2015. PMID: 25637715 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical